Adama Gansané1, Leah F Moriarty2, Didier Ménard3, Isidore Yerbanga4, Esperance Ouedraogo5, Paul Sondo4, Rene Kinda5, Casimir Tarama5, Edwige Soulama5, Madou Tapsoba5, David Kangoye5, Cheick Said Compaore6, Ousmane Badolo7, Blami Dao7, Samuel Tchwenko2, Halidou Tinto4, Innocent Valea4. 1. Centre National de Recherche Et de Formation Sur Le Paludisme, Ouagadougou, Burkina Faso. agansane@hotmail.com. 2. Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, US President's Malaria Initiative, Atlanta, GA, USA. 3. Malaria Genetics and Resistance Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France. 4. IRSS / Unité de Recherche Clinique de Nanoro, Nanoro, Burkina Faso. 5. Centre National de Recherche Et de Formation Sur Le Paludisme, Ouagadougou, Burkina Faso. 6. National Malaria Control Programme, Ouagadougou, Burkina Faso. 7. JHPIEGO/ Improving Malaria Care, Ouagadougou, Burkina Faso.
Abstract
BACKGROUND: The World Health Organization recommends regularly assessing the efficacy of artemisinin-based combination therapy (ACT), which is a critical tool in the fight against malaria. This study evaluated the efficacy of two artemisinin-based combinations recommended to treat uncomplicated Plasmodium falciparum malaria in Burkina Faso in three sites: Niangoloko, Nanoro, and Gourcy. METHODS: This was a two-arm randomized control trial of the efficacy of artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP). Children aged 6-59 months old were monitored for 42 days. The primary outcomes of the study were uncorrected and PCR-corrected efficacies to day 28 for AL and 42 for DP. Molecular markers of resistance to artemisinin derivatives and partner drugs were also analysed. RESULTS: Of 720 children enrolled, 672 reached study endpoints at day 28, 333 in the AL arm and 339 in the DP arm. PCR-corrected 28-day per protocol efficacy in the AL arm was 74% (64-83%) in Nanoro, 76% (66-83%) in Gourcy, and 92% (84-96%) in Niangoloko. The PCR-corrected 42-day per protocol efficacy in the DP arm was 84% (75-89%) in Gourcy, 89% (81-94%) in Nanoro, and 97% (92-99%) in Niangoloko. No Pfk13 mutation previously associated with artemisinin-resistance was observed. No statistically significant association was found between treatment outcome and presence of the 86Y mutation in the Pfmdr1 gene. There was also no association observed between treatment outcome and Pfpm2 or Pfmdr1 copy number variation. CONCLUSION: The results of this study indicate evidence of inadequate efficacy of AL at day 28 and DP at day 42 in the same two sites. A change of first-line ACT may be warranted in Burkina Faso. Trial Registry Pan African Clinical Trial Registry Identifier: PACTR201708002499311. Date of registration: 8/3/2017 https://pactr.samrc.ac.za/Search.aspx.
RCT Entities:
BACKGROUND: The World Health Organization recommends regularly assessing the efficacy of artemisinin-based combination therapy (ACT), which is a critical tool in the fight against malaria. This study evaluated the efficacy of two artemisinin-based combinations recommended to treat uncomplicated Plasmodium falciparummalaria in Burkina Faso in three sites: Niangoloko, Nanoro, and Gourcy. METHODS: This was a two-arm randomized control trial of the efficacy of artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP). Children aged 6-59 months old were monitored for 42 days. The primary outcomes of the study were uncorrected and PCR-corrected efficacies to day 28 for AL and 42 for DP. Molecular markers of resistance to artemisinin derivatives and partner drugs were also analysed. RESULTS: Of 720 children enrolled, 672 reached study endpoints at day 28, 333 in the AL arm and 339 in the DP arm. PCR-corrected 28-day per protocol efficacy in the AL arm was 74% (64-83%) in Nanoro, 76% (66-83%) in Gourcy, and 92% (84-96%) in Niangoloko. The PCR-corrected 42-day per protocol efficacy in the DP arm was 84% (75-89%) in Gourcy, 89% (81-94%) in Nanoro, and 97% (92-99%) in Niangoloko. No Pfk13 mutation previously associated with artemisinin-resistance was observed. No statistically significant association was found between treatment outcome and presence of the 86Y mutation in the Pfmdr1 gene. There was also no association observed between treatment outcome and Pfpm2 or Pfmdr1 copy number variation. CONCLUSION: The results of this study indicate evidence of inadequate efficacy of AL at day 28 and DP at day 42 in the same two sites. A change of first-line ACT may be warranted in Burkina Faso. Trial Registry Pan African Clinical Trial Registry Identifier: PACTR201708002499311. Date of registration: 8/3/2017 https://pactr.samrc.ac.za/Search.aspx.
Authors: André Lin Ouédraogo; Bronner P Gonçalves; Awa Gnémé; Edward A Wenger; Moussa W Guelbeogo; Amathe Ouédraogo; Jaline Gerardin; Caitlin A Bever; Hil Lyons; Xavier Pitroipa; Jan Peter Verhave; Philip A Eckhoff; Chris Drakeley; Robert Sauerwein; Adrian J F Luty; Bocar Kouyaté; Teun Bousema Journal: J Infect Dis Date: 2015-07-03 Impact factor: 5.226
Authors: Halidou Tinto; Salou Diallo; Issaka Zongo; Issa Guiraud; Innocent Valea; Adama Kazienga; Hervé Kpoda; Hermann Sorgho; Jean-Bosco Ouédraogo; Tinga Robert Guiguemdé; Umberto D'Alessandro Journal: Trop Med Int Health Date: 2014-02-05 Impact factor: 2.622
Authors: Meera Venkatesan; Nahla B Gadalla; Kasia Stepniewska; Prabin Dahal; Christian Nsanzabana; Clarissa Moriera; Ric N Price; Andreas Mårtensson; Philip J Rosenthal; Grant Dorsey; Colin J Sutherland; Philippe Guérin; Timothy M E Davis; Didier Ménard; Ishag Adam; George Ademowo; Cesar Arze; Frederick N Baliraine; Nicole Berens-Riha; Anders Björkman; Steffen Borrmann; Francesco Checchi; Meghna Desai; Mehul Dhorda; Abdoulaye A Djimdé; Badria B El-Sayed; Teferi Eshetu; Frederick Eyase; Catherine Falade; Jean-François Faucher; Gabrielle Fröberg; Anastasia Grivoyannis; Sally Hamour; Sandrine Houzé; Jacob Johnson; Erasmus Kamugisha; Simon Kariuki; Jean-René Kiechel; Fred Kironde; Poul-Erik Kofoed; Jacques LeBras; Maja Malmberg; Leah Mwai; Billy Ngasala; Francois Nosten; Samuel L Nsobya; Alexis Nzila; Mary Oguike; Sabina Dahlström Otienoburu; Bernhards Ogutu; Jean-Bosco Ouédraogo; Patrice Piola; Lars Rombo; Birgit Schramm; A Fabrice Somé; Julie Thwing; Johan Ursing; Rina P M Wong; Ahmed Zeynudin; Issaka Zongo; Christopher V Plowe; Carol Hopkins Sibley Journal: Am J Trop Med Hyg Date: 2014-07-21 Impact factor: 2.345
Authors: Eric M Foote; Kevin M Sullivan; Laird J Ruth; Jared Oremo; Ibrahim Sadumah; Thomas N Williams; Parminder S Suchdev Journal: Am J Trop Med Hyg Date: 2013-02-04 Impact factor: 2.345
Authors: Toussaint Rouamba; Paul Sondo; Isidore W Yerbanga; Adelaide Compaore; Maminata Traore-Coulibaly; Franck S Hien; Nassirou A Diande; Innocent Valea; Marc Christian Tahita; Rita Baiden; Fred Binka; Halidou Tinto Journal: Pharmacol Res Perspect Date: 2022-08
Authors: Freek de Haan; Oladimeji Akeem Bolarinwa; Rosemonde Guissou; Fatoumata Tou; Paulina Tindana; Wouter P C Boon; Ellen H M Moors; Phaik Yeong Cheah; Mehul Dhorda; Arjen M Dondorp; Jean Bosco Ouedraogo; Olugbenga A Mokuolu; Chanaki Amaratunga Journal: PLoS One Date: 2021-08-31 Impact factor: 3.240
Authors: Catherine M Dentinger; Tovonahary Angelo Rakotomanga; Antsa Rakotondrandriana; Arinomenjanahary Rakotoarisoa; Marie Ange Rason; Leah F Moriarty; Laura C Steinhardt; Laurent Kapesa; Jocelyn Razafindrakoto; Samaly S Svigel; Naomi W Lucchi; Venkatachalam Udhayakumar; Eric S Halsey; C Arsène Ratsimbasoa Journal: Malar J Date: 2021-11-03 Impact factor: 2.979